The efficacy of myo-inositol supplementation to reduce the incidence of gestational diabetes: a meta-analysis.

INTRODUCTION

Myo-inositol supplementation is used to reduce the incidence of gestational diabetes, but its efficacy is not well established. This meta-analysis aims to explore the influence of myo-inositol supplementation on the prevention of gestational diabetes.

METHODS

This meta-analysis has been conducted up to March 2022 to identify randomized clinical trials comparing the efficacy of myo-inositol supplementation to prevent gestational diabetes. Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systemically.

RESULTS

We have included eight RCTs in this meta-analysis. Compared with control group in pregnant women, myo-inositol supplementation was found to significantly decrease the incidence of gestational diabetes (OR = 0.40; 95% CI = 0.19 to 0.84;  = .01), 2-h glucose OGTT (SMD = -0.22; 95% CI = -0.41 to -0.02;  = .03), HOMA-IR (SMD = -0.25; 95% CI = -0.42 to -0.08;  = .004) and preterm delivery (OR = 0.41; 95% CI = 0.23 to 0.73;  = .003), but demonstrated no obvious impact on gestational age at birth (SMD = 0.12; 95% CI = -0.05 to 0.29;  = .18) or birth weight (SMD = -0.04; 95% CI = -0.20 to 0.13;  = .68).

CONCLUSIONS

Myo-inositol supplementation is effective to reduce the incidence of gestational diabetes, 2-h glucose OGTT, HOMA-IR and preterm delivery, which suggested that myo-inositol supplementation should be recommended to prevent gestational diabetes.